Tatsuro Fukuhara

Dr. Tatsuro Fukuhara

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2021 in Nature
Verified
Journal Article
Closed access
PDF file
HIHiroki Izumi
Hiroki Izumi
SMShingo Matsumoto
Shingo Matsumoto
JLJie Liu
Jie Liu
KTKosuke Tanaka
Kosuke Tanaka
SMShunta Mori
Shunta Mori
KGKoichi Goto
Koichi Goto

20 June 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SMSatoru Miura
Satoru Miura
HTHiroshi Tanaka
Hiroshi Tanaka
TMToshihiro Misumi
Toshihiro Misumi
HYHiroshige Yoshioka
Hiroshige Yoshioka
TTTakaaki Tokito
Takaaki Tokito
OIon behalf of the Thoracic Oncology Research Group and all ACHILLES investigators
on behalf of the Thoracic Oncology Research Group and all ACHILLES investigators
PURPOSE: To our knowledge, the ACHILLES/TORG1834 trial is the first randomized study comparing afatinib and chemotherapy in patients with non–small cell lung cancer (NSCLC) harboring sensitizing uncommon epidermal growth factor receptor ( EGFR ) mutations. METHODS: This randomized, open-label study was performed at 51 Japanese institutions and recruited treatment-naïve patients with nonsquamous NSCLC with uncommon EGFR mutations, excluding exon 20 insertions and T790M mutations. Patients were randomly assigned 2:1 to receive afatinib (30 or 40 mg orally, at the treating physician's discretion) or a combination of platinum (cisplatin or carboplatin) and pemetrexed, followed by pemetrexed maintenance. The primary end point was progression-free survival (PFS). Secondary end points included objective response rate (ORR), overall survival, and safety. A prespecified interim analysis was planned to provide clinically meaningful information promptly, along with a crossover recommendation if necessary. RESULTS: A total of 109 patients were enrolled between March 2019 and February 2023. In the interim analysis, the Data and Safety Monitoring Committee recommended early study termination. The median PFS was significantly longer in patients receiving afatinib than in those undergoing chemotherapy (10.6 v 5.7 months; hazard ratio, 0.421 [95% CI, 0.251 to 0.706]; P = .0010). ORRs to afatinib were similar across the overall population and among participants with major uncommon (G719X, L861Q, and S768I), compound, and other mutations (61.7%, 55.8%, 72.7%, and 60.0%, respectively). The most common grade 3 or higher adverse events were diarrhea, paronychia, and rash for afatinib, and appetite loss and nausea for chemotherapy. CONCLUSION: Afatinib should be considered the standard initial therapy for patients with NSCLC with sensitizing uncommon EGFR mutations.

13 December 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MNMiyuki Nomura
Miyuki Nomura
MOMai Ohuchi
Mai Ohuchi
YSYoshimi Sakamoto
Yoshimi Sakamoto
KKKei Kudo
Kei Kudo
KYKeisuke Yaku
Keisuke Yaku
NTNobuhiro Tanuma
Nobuhiro Tanuma
Nicotinamide phosphoribosyltransferase (NAMPT) plays a major role in NAD biosynthesis in many cancers and is an attractive potential cancer target. However, factors dictating therapeutic efficacy of NAMPT inhibitors (NAMPTi) are unclear. We report that neuroendocrine phenotypes predict lung and prostate carcinoma vulnerability to NAMPTi, and that NAMPTi therapy against those cancers is enhanced by dietary modification. Neuroendocrine differentiation of tumor cells is associated with down-regulation of genes relevant to quinolinate phosphoribosyltransferase-dependent de novo NAD synthesis, promoting NAMPTi susceptibility in vitro. We also report that circulating nicotinic acid riboside (NAR), a non-canonical niacin absent in culture media, antagonizes NAMPTi efficacy as it fuels NAMPT-independent but nicotinamide riboside kinase 1-dependent NAD synthesis in tumors. In mouse transplantation models, depleting blood NAR by nutritional or genetic manipulations is synthetic lethal to tumors when combined with NAMPTi. Our findings provide a rationale for simultaneous targeting of NAR metabolism and NAMPT therapeutically in neuroendocrine carcinoma.

1 December 2014 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
ZWZenta Watanuki
Zenta Watanuki
HKHitomi Kosai
Hitomi Kosai
NONanae Osanai
Nanae Osanai
NONaoko Ogama
Naoko Ogama
MMMai Mochizuki
Mai Mochizuki
NTNobuyuki Tanaka
Nobuyuki Tanaka

1 July 2020 in EBioMedicine
Verified
Journal Article
Open access
TFTatsuro Fukuhara
Tatsuro Fukuhara
HSHaruhiro Saito
Haruhiro Saito
NFNaoki Furuya
Naoki Furuya
KWKana Watanabe
Kana Watanabe
SSShunichi Sugawara
Shunichi Sugawara
MMMakoto Maemondo
Makoto Maemondo
The NEJ026 Phase 3 study demonstrated that erlotinib and bevacizumab (BE)-treated NSCLC patients with EGFR mutations had significantly better progression-free survival (PFS) than those treated with erlotinib alone (E). This study included a prospective analysis of the relationship between the mutational status of EGFR in plasma circulating tumor DNA (ctDNA) and the efficacy of TKI monotherapy or combination therapy. We describe these results herein. Plasma samples were collected from patients enrolled in NEJ026 at the start of treatment (P0), 6 weeks after the start of treatment (P1), and upon confirmation of progressive disease (P2). Plasma ctDNA was analyzed using a modified PNA-LNA PCR clamp method. PFS and OS according to EGFR status at the time of plasma collection were evaluated. Plasma activating EGFR mutation (aEGFR) at P0 was detected in 68% of cases; patients without plasma aEGFR had longer PFS. The frequency of T790M mutation at P2 was similar in both arms: 8 (19.0%) in BE and 11 (20.8%) in E. Based on the aEGFR profiles, PFS was evaluated among three groups: type A [P0(-), P1(-)], type B [P0(+), P1(-)], and type C [P0(+), P1(+)]. This revealed that BE was more efficacious than E, and that BE was associated with improved PFS in all types. Pre-treatment plasma aEGFR status have a potential of early predictor of response of TKI efficacy. Monitoring plasma aEGFR mutation will contribute to selection and continuation of treatment with BE or E. Chugai Pharmaceutical.

1 May 2015 in Lung Cancer
Verified
Journal Article
Open access
TFTatsuro Fukuhara
Tatsuro Fukuhara
MMMakoto Maemondo
Makoto Maemondo
AIAkira Inoue
Akira Inoue
KKKunihiko Kobayashi
Kunihiko Kobayashi
SSShunichi Sugawara
Shunichi Sugawara
TNToshihiro Nukiwa
Toshihiro Nukiwa
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment is the standard therapy for non-small cell lung cancer (NSCLC) harbouring EGFR-activating mutations. The NEJ002 phase 3 clinical trial demonstrated the efficacy of EGFR-TKI; gefitinib was significantly superior in both progression-free survival (PFS) and objective response rate (ORR) than carboplatin plus paclitaxel. However, several cases showed no response. In this study, we performed further analysis of the characteristics of these non-responders. Available data from NEJ002 on maximum changes in tumour size were obtained from 103 cases (90.4%) and 110 cases (96.5%) in the carboplatin-paclitaxel and gefitinib groups, respectively. Waterfall plots of maximum tumour size changes were created for non-responders. Five (4.9%) and 9 (8.2%) cases in the carboplatin-paclitaxel and gefitinib groups were non-responders, respectively. The mean pack years of the non-responders in the carboplatin-paclitaxel and gefitinib groups were 0.33 and 31.7, respectively. The ORR of total smokers (61.5%) and heavy smokers (over 40 pack years, 52.6%) in the gefitinib group were significantly lower compared to people who have never smoked (80.0%) (P=0.044 and P=0.020, respectively). Smoker cases also showed a tendency towards lower PFS and overall survival (OS). In addition, the EGFR common mutation types did not affect PFS and OS in gefitinib-treated cases in NEJ002. However, in this study, the ORR and waterfall plots showed that gefitinib-treated non-responders who had a deletion in exon 19 in the EGFR gene exhibited a tendency towards a higher response compared to those with a L858R mutation. NSCLC patients with a smoking history or the EGFR L858R mutation may demonstrate a poorer response to gefitinib treatment.